Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review

References

• aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. 2010. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 67:139–145.
   PubMed Web of Science ®Google Scholar
• Abelaira HM, Reus GZ, Neotti MV, Quevedo J. 2014. The role of mTOR in depression and antidepressant responses. Life Sci. 101:10–14.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Pinault D, O'Brien TJ, Jones NC. 2014. Chronic administration of antipsychotics attenuates ongoing and ketamine-induced increases in cortical γ oscillations. . Int J Neuropsychopharmacol. 17:1895–1904.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 47:351.
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR. 2013. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 38:729–742.
   PubMed Web of Science ®Google Scholar
• Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Manji HK, Zarate CA Jr, Drevets WC. 2013. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 73:1213–1221.
   PubMed Web of Science ®Google Scholar
• Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB. 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 36:71–76.
   PubMedGoogle Scholar
• Correll GE, Futter GE. 2006. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 7:92–95.
   PubMed Web of Science ®Google Scholar
• Coyle CM, Laws KR. 2015. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol. 30:152–163.
   PubMed Web of Science ®Google Scholar
• Cusin C, Hilton GQ, Nierenberg AA, Fava M. 2012. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 169:868–869.
   PubMed Web of Science ®Google Scholar
• De Gioannis A, De Leo D. 2014. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 48:686
   PubMed Web of Science ®Google Scholar
• Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R. 2014. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol (Oxford). 28:536–544.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 67:793–802.
   PubMed Web of Science ®Google Scholar
• Duman RS, Li N. 2012. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci. 367:2475–2484.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. 2009. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 60:1439–1445.
   PubMed Web of Science ®Google Scholar
• Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM. 2013. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 70:668–676.
   PubMed Web of Science ®Google Scholar
• Harihar C, Dasari P, Srinivas JS. 2013. Intramuscular ketamine in acute depression: a report on two cases. Indian J Psychiatry. 55:186–188.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. 2014. The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression. Clin Psychopharmacol Neurosci. 12:72–73.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr. 2011. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 35:1155–1159.
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS. 2013. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 16:958–965.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. 2006. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 163:1561–1568.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK. 2014. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 15:579–584.
   PubMed Web of Science ®Google Scholar
• Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. 2014. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biol Psychiatry. 76:970–976.
   PubMed Web of Science ®Google Scholar
• Lara DR, Bisol LW, Munari LR. 2013. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 16:2111–2117.
   PubMed Web of Science ®Google Scholar
• Larkin GL, Beautrais AL. 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 14:1127–1131.
   PubMed Web of Science ®Google Scholar
• Lee EE, Della Selva MP, Liu A, Himelhoch S. 2015. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 37:178–184.
   PubMed Web of Science ®Google Scholar
• Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, et al. 2014. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. J Clin Psychopharmacol. 34:337–343.
   PubMed Web of Science ®Google Scholar
• Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. 2012. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 142:233–240.
   PubMed Web of Science ®Google Scholar
• Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richard EM, Brutsche NE, Guevara S, Zarate CA. 2014. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 159:56–61.
   PubMed Web of Science ®Google Scholar
• Maia-de-Oliveira JP, Lobao-Soares B, Ramalho T, Gavioli EC, Soares VP, Teixeira L, Baker GB, Dursun SM, Hallak JEC. 2015. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res. 162:211–215.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 13:71–82.
   PubMed Web of Science ®Google Scholar
• Mathews DC, Zarate CA. Jr. 2013. Current status of ketamine and related compounds for depression. J Clin Psychiatry. 74:516–517.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. 2014. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 45:693–704.
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD. 2014. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 23:243–254.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, et al. 2013a. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 170:1134–1142.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. 2013b. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 74:250–256.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. 2014. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 54:119–139.
   PubMed Web of Science ®Google Scholar
• Owen RT. 2012. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc). 48:469–478.
   PubMed Web of Science ®Google Scholar
• Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S. 2013. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord. 147:431–436.
   PubMed Web of Science ®Google Scholar
• Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. 2010. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 43:33–35.
   PubMed Web of Science ®Google Scholar
• Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T. 2009. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry. 10:241–244.
   PubMed Web of Science ®Google Scholar
• Pochwat B, Palucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G. 2014. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs. 23:1181–1192.
   PubMed Web of Science ®Google Scholar
• Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, GLYX-13 Clinical Study Group. 2015. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 21:140–149.
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. 2013. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol (Oxford). 27:444–450.
   PubMed Web of Science ®Google Scholar
• Salvadore G, Singh JB. 2013. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 19:428–436.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Schatzberg AF. 2015. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 40:259–267.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. 2014. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 19:978–985.
   PubMed Web of Science ®Google Scholar
• Segmiller F, Ruther T, Linhardt A, Padberg F, Berger M, Pogarell O, Möller HJ, Kohler C, Schüle C. 2013. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol. 53:996–998.
   PubMed Web of Science ®Google Scholar
• Serafini G, Howland RH, Rovedi F, Girardi P, Amore M. 2014. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 12:444–461.
   PubMed Web of Science ®Google Scholar
• Singh J, Fedgchin M, Daly E, Xi L, Hulihan J, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, et al. 2014. Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-Resistant Depression: A Double-blind, Double-randomization, Placebo-controlled Phase 2a Study. 14th International Forum on Mood and Anxiety Disorders, 10-12 December, 2014. Vienna.
   Google Scholar
• Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. 2013. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 74:966–973.
   PubMed Web of Science ®Google Scholar
• Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. 2013. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 34:287–293.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. 2013. Serotonergic drugs for depression and beyond. Curr Drug Targets. 14:578–585.
   PubMed Web of Science ®Google Scholar
• Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. 2015. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 76:247–252.
   PubMed Web of Science ®Google Scholar
• WHO. 2012. RE: Depression Fact Sheet.
   Google Scholar
• Zanicotti CG, Perez D, Glue P. 2012. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 15:400–403.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. 2013. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry. 74:257–264.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006a. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63:856–864.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. 2006b. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 163:153–155.
   PubMed Web of Science ®Google Scholar
• Zhang JC, Li SX, Hashimoto K. 2014. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 116:137–141.
   PubMed Web of Science ®Google Scholar
• Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. 2013. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry. 18:1236–1241.
   PubMed Web of Science ®Google Scholar